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Tissue kallikrein (kallikrein 1) was first identified in pan-
creas and is the namesake of the kallikrein-related pep-
tidase (KLK) family. KLK1 and the other 14 members of
the human KLK family are encoded by 15 serine protease
genes clustered at chromosome 19q13.4. Our Northern
blot analysis of 19 normal human tissues for expression
of KLK4 to KLK15 identified pancreas as a common
expression site for the gene cluster spanning KLK5 to
KLK13, as well as for KLK15 which is located adjacent
to KLK1. Consistent with previous reports detailing the
ability of KLK genes to generate organ- and disease-
specific transcripts, detailed molecular and in silico anal-
yses indicated that KLK5 and KLK7 generate transcripts
in pancreas variant from those in skin or ovary. Consis-
tently, we identified in the promoters of these KLK genes
motifs which conform with consensus binding sites for
transcription factors conferring pancreatic expression. In
addition, immunohistochemical analysis revealed pre-
dominant localisation of KLK5 and KLK7 in acinar cells
of the exocrine pancreas, suggesting roles for these
enzymes in digestion. Our data also support expression
patterns derived from gene duplication events in the
human KLK cluster. These findings suggest that, in add-
ition to KLK1, other related KLK enzymes will function in
the exocrine pancreas.
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Introduction
Tissue kallikrein or kallikrein 1 (KLK1/KLK1) was the first
described member and namesake of a gene family,
encoding 15 serine proteases, localized in a discrete
gene cluster on chromosome 19q13.4 (Gan et al., 2000;
Harvey et al., 2000; Yousef and Diamandis, 2001). Tissue
kallikrein was first identified in pancreatic extract (Kraut
et al., 1930) and pancreas is still recognised as a site of
most abundant KLK1 expression (Fukushima et al., 1985;
Clements, 1997). In this and other organs, KLK1, princi-
pally via kinin generation, is involved in the regulation of
local blood flow and pressure, vascular permeability and
inflammation and has been implicated in pathophysio-
logical processes in the cardiovascular, respiratory, renal,
gastrointestinal, reproductive and central nervous sys-
tems (Clements, 1997). Similar to KLK1, the other 14 KLK
proteases function in post-translational modification of
polypeptides, including activation of other KLKs and
growth factors and degradation/remodelling of the extra-
cellular matrix. These proteolytic events regulate diverse
cellular processes, including proliferation differentiation,
and angiogenesis, as well as a variety of pathophysio-
logical processes in organs, such as the prostate, ovary,
brain and skin (Borgono and Diamandis, 2004; Clements
et al., 2004). However, little attention has been focussed
on the potential function and/or expression of the more
recently identified KLKs (KLK4–KLK15) in the pancreas.
A feature of the KLK gene family is the discrepancy
apparent in expression patterns when comparing data
generated by Northern blot and reverse transcription-
polymerase chain reaction (RT-PCR) analysis; tight tis-
sue-restricted expression is generally observed by
Northern blot analysis, whereas broader expression is
often observed by RT-PCR analysis (Harvey et al., 2000).
Additionally, these analyses have indicated that clusters
of KLK locus genes show common sites of expression.
For instance, the contiguous KLK15-KLK3-KLK2-KLK4
genes have a common prostatic expression (Harvey et
al., 2000). Similarly, the contiguous KLK4–KLK11 and
KLK13–14 genes are highly expressed in ovarian cancer
(Yousef and Diamandis, 2001; Clements et al., 2004).
Furthermore, KLK6, KLK8 and KLK15 are highly
expressed in the central nervous system (Yousef and
Diamandis, 2001; Clements et al., 2004). These data gen-
erally support the notion of gene duplication within this
locus (Lundwall et al., 2006) and common DNA elements
regulating tissue-specific expression. In this regard, we
have previously shown using mRNA dot blot analysis that
the KLK6–KLK13 cluster of genes exhibit high pancreatic
expression (Harvey et al., 2000). Surprisingly, using the
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Figure 1 Expression of KLKs in normal human tissues by
Northern blot analysis.
Human multiple tissue mRNA blots were hybridised with
w32Px-labelled cRNA probes for KLK4–15 as shown on the left-
hand side of the panel, or a w32Px-random-labelled b-actin
cRNA probe. The transcript lengths are indicated on the right.
more sensitive RT-PCR approach, only KLK10 and
KLK12 showed expression in the pancreas (Gan et al.,
2000; Harvey et al., 2000). The reason for this discrep-
ancy remains unknown.
A second feature of the KLK family is the extraordinary
number of mRNA splice variants. To date, more than 80
splice variants have been described for the 15 KLK
genes, with only a small number of these characterised
to any extent (Kurlender et al., 2005; Tan et al., 2006).
The tissue- and disease-specific expression of these
characterised transcripts has led to the proposal that
KLK splice variants may provide useful biomarkers for
several diseases (Tan et al., 2006). Interestingly, most of
these splice variants have been discovered by analysis
of expressed sequence tag (EST) databases, and thus
do not have complete 59-sequences. Therefore, differ-
ences between the 59-untranslated regions (UTRs) or
proximal promoters of the majority of KLK variant tran-
scripts are unknown. In this respect, we have previously
described novel KLK5 and KLK7 transcripts in ovarian
cancer cells that have different 59-sequences to those
first described in skin (Dong et al., 2003). This potentially
indicates that these variant transcripts or the encoded
proteins will have tissue- or disease-specific roles.
In this study, using Northern blot analysis, we have
identified a cluster of KLK genes with high pancreatic
expression. We have further investigated the KLK5 and
KLK7 transcripts expressed in the pancreas comparing
these to transcripts generated in skin or ovary. We also
provide evidence for tissue- and disease-specific tran-
scriptional regulation of KLK expression. Finally, we have
determined the cellular localisation of KLK5 and KLK7 in
pancreatic tissue samples, providing for the first time
insight into potential roles for these proteases in the
pancreas.
Results
High expression of KLK gene clusters in the
pancreas
To identify common sites of mRNA expression of
KLK4–15, 19 normal human tissues were examined by
Northern blot analysis using probes specific to each KLK.
The autoradiographs obtained are shown in Figure 1,
with a summary and comparison with KLK1–KLK3 in
Table 1. Strong hybridisation was clearly observed in the
pancreas for KLK5, KLK8 and KLK10, and at a moderate
level for KLK7, KLK9, KLK11–13 and KLK15, suggesting
that this is the major site of expression for these KLK
genes. Faint hybridisation was also observed for KLK6.
A strong KLK4 mRNA band was only detected in the
prostate, indicating that similar to KLK2 and KLK3, KLK4
expression is prostate restricted. In addition, KLK8,
KLK10, KLK11, KLK14 and KLK15 hybridisation was also
observed in the prostate. Testis showed strong KLK5
hybridisation, while a faint KLK5 band was observed in
intestine and uterus. Similarly, a strong KLK6 hybridisa-
tion was observed in the prostate, and less intense
bands for KLK6 were observed in heart and kidney, pan-
creas, spleen and ovary. KLK10 was additionally detect-
ed in thymus, testis and ovary, whereas KLK11 and
KLK12 were also expressed in testis and muscle, respect-
ively. Consistently, serial analysis of gene expression
(SAGE; SAGEmap database), virtual Northern blotting
and EST database searches detected pancreatic tran-
scripts for KLK5, 6, and 11 (GenBank: AF168768,
AF013988 and AB012917; SAGEmap database), and
KLK1, KLK7 and KLK10 (GenBank: BC005313, L33404
and BC002710; both SAGEmap database and EST data-
base) (Table 2). Taken together with published data
(Fukushima et al., 1985; Harvey et al., 2000), the
pancreas showed common expression through the con-
tiguous gene clusters of KLK1–KLK15 and KLK5–13,
with the pancreas being the most abundant site of
expression for KLK5, KLK7–KLK10, KLK12, KLK13 and
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Table 1 KLK expression levels from Northern blot analysis.
Genes Tissues with intense or faint Approximate References
hybridisation bands transcript size (kb)
KLK1 Pancreas, kidney, salivary gland 0.9 Fukushima et al., 1985
KLK2 Prostate 1.2, 1.5 Riegman et al., 1991
KLK3 Prostate 1.6, 2.1, 3.1, 5.2, 6.1 Heuze-Vourc’h et al., 2003
KLK4 Prostate 1.35
KLK5 Pancreas, testis, prostate, intestine, uterus 1.0, 1.35
KLK6 Heart, prostate, kidney, pancreas, spleen, ovary 1.0, 1.35, 3.0, 4.4, 6.0
KLK7 Pancreas 1.0
KLK8 Pancreas, prostate 1.2, 2.0
KLK9 Pancreas 1.0, 2.5
KLK10 Pancreas, thymus, prostate, testis, ovary 1.0, 1.35
KLK11 Pancreas, prostate, testis 1.0, 1.35
KLK12 Pancreas, muscle 1.0, 1.6
KLK13 Pancreas 1.0
KLK14 Prostate, skeletal muscle 2.0, 1.35
KLK15 Pancreas, prostate, testis 1.0, 1.35
Table 2 In silico analysis of KLK expression in the pancreas
using SAGEmap and EST databases.
Kallikrein SAGEmap EST database
Normal Carcinoma Normal Carcinoma
(3a) (6a) (9a) (10a)
KLK1 1/3 2/6 2/9 2/10
KLK5 1/3 0/6 0/9 0/10
KLK6 1/3 4/6 0/9 0/10
KLK7 0/3 2/6 0/9 1/10
KLK10 0/3 4/6 0/9 3/10
KLK11 0/3 3/6 0/9 0/10
aTotal clone number in the NCBI database (http://www.ncbi.
nlm.nih.gov).
KLK15. Notably, expression of KLK7 and KLK13 was
restricted to the pancreas.
It was of interest to note that multiple bands were
observed in certain tissues, such as KLK6 in prostate
(1.35, 3.0, 4.4, 6.0 kb) and KLK9 in pancreas (1.0, 2.5 kb)
(Figure 1), suggesting the existence of multiple KLK
mRNA transcripts. Additionally, mRNA transcripts with
different sizes were observed between the pancreas and
other tissues for KLK5, KLK6, KLK8 and KLK10–12 (Fig-
ure 1). For instance, all pancreatic transcripts (KLK5–13
and KLK15) are approximately 1.0 kb and similar in size
to the KLK10 transcript in thymus and KLK15 in testis.
However, the transcripts expressed in other tissues
appear larger – notably approximately 1.35 kb for pros-
tatic KLK4, KLK6, KLK10, KLK11, KLK14 and KLK15,
testicular KLK5, KLK10 and KLK11, ovarian KLK6 and
KLK10, and heart, kidney and spleen KLK6, with a ca.
2.0 kb KLK8 transcript also observed in the prostate.
Taken together with previous studies (Harvey et al.,
2000), the various mRNA transcript sizes from different
tissues for each KLK gene indicated the existence of
tissue-specific KLK mRNA transcripts.
Identification of pancreas-specific KLK5 and KLK7
transcripts
Owing to differences in the size of KLK5 and KLK7 tran-
scripts in pancreas compared with transcripts from other
tissues, we obtained the complete cDNA sequence of the
pancreatic transcripts produced from each of these
genes by transcription initiation site (TIS) identification
(through RNA ligase-mediated rapid amplification of
cDNA ends, RLM-RACE) and 39-RACE, as well as
sequencing of a pancreatic EST clone.
Figure 2A,B shows the 59- and 39-RACE products,
respectively, for KLK5 in the pancreas, with control reac-
tions on RNA from HaCat and OVCAR-3 cells. The
regions amplified for each tissue-specific product (bands
1–5) are indicated schematically in Figure 2C. Sequenc-
ing of 59-RACE products indicted that the transcription of
KLK5 was initiated from the same site in pancreas (band
1), HaCat cells (short form, band 3) and ovary (short form,
AF435981, Figure 2C). In addition, our sequencing data
showed that the HaCat long and OVCAR-3 transcripts
(Figure 2A, bands 2 and 4; AF435980) have an additional
40 bp at the 59-end (exon 1b) compared with the previ-
ously published skin KLK5 transcript (exon 1c,
NM_012427). Using the 39-primer set (exons 4–5), indi-
cated in Figure 2C, KLK5 39-UTR bands of the same size
were observed from pancreas and the cell lines HaCat
and OVCAR-3 (band 5, Figure 2B), which gave an equiv-
alent 39-UTR sequence to that identified in skin
(NM_012427) (Brattsand and Egelrud, 1999). No band
was observed in the negative (without cDNA) control (Fig-
ure 2A,B). Of note, the KLK5 transcripts in different tis-
sues have the same coding region which encodes
pre-pro-KLK5, though alternative 59-UTRs are clearly uti-
lised, giving rise to exons 1a, 1b and 1c that are specif-
ically expressed in pancreas (1a), skin (1a, 1b and 1d) or
ovary (1b and 1c).
The comparison of 59- and 39-UTR for KLK7 in the pan-
creas and HaCat and OVCAR-3 cells are shown in Figure
3. Sequencing of 59-RLM-RACE products revealed that
pancreatic KLK7 59-UTR (band 1) is 121 bp shorter (exon
1a) than that of HaCat (bands 2 and 3) and OVCAR-3
cells (band 4, exon 1c), but has 110 bp of further 59-UTR
sequence upstream of the reported skin transcript
(L33404, Figure 3C). The pancreatic KLK7 59-UTR
sequence also has an additional 19 bp in comparison to
the sequence reported for the pancreatic EST clone
(GenBank AA101043, data not shown). Two pancreatic
KLK7 39-bands (bands 5 and 6) of 1300 bp and 1050 bp,
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Figure 2 Identification of 59- and 39-sequences of tissue-specific KLK5 transcripts.
(A) 59-RLM-RACE products from pancreatic, HaCat and OVCAR-3 RNA with (q) or without (-) tobacco alkaline pyrophosphatase (TAP)
treatment as indicated. (B) 39-RACE products from the above RNA. (C) Schematic representation of KLK5 transcripts from the above
tissues in comparison to transcripts from skin (NM_012427). Shaded boxes, coding exons; open boxes, non-coding exons. Introns
are shown as lines. Size of exons and introns with nucleotide number is indicated. AF435980, AF435981 and NM_012427, GenBank
accession number. The primer sets (1–5) used to generate the PCR products (1–5) in panels (A) and (B) and the product sizes are
indicated.
Figure 3 Identification of 59- and 39-sequences of tissue-specific KLK7 transcripts.
(A) 59-RLM-RACE products from the pancreatic, HaCat and OVCAR-3 RNA with (q) or without (-) TAP treatment as indicated, with
no TAP treated RNA as a control reaction. (B) 39-RACE products from pancreas RNA. (C) Schematic representation of KLK7 transcripts
from the above tissues in comparison to transcripts from ovary (AF411214 and AF411215) and skin (L33404). Pancreatic EST entries
(AA101043 and AA101044) are shown for comparison. Shaded boxes, coding exons; open boxes, non-coding exons. Introns are
shown as lines. Size of exons and introns with nucleotide number is indicated. GenBank accession numbers are indicated in brackets.
The primer sets (1–6) used in the panels (A) and (B) and the product size are indicated.
respectively, were amplified. The no cDNA control was
appropriately negative (Figure 3A,B). The schematic
alignment of sequences obtained from the pancreas,
HaCat and OVCAR-3 cells and skin (L33404) (Hansson
et al., 1994) compared to ovary and skin (exon 1c) is
shown in Figure 3C. These data show that different
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Figure 4 Sequence analysis of the human KLK5 promoter.
(A) Nucleotide sequence of the proximal promoter and 59-flanking region of KLK5. The TIS is indicated by the arrow and a putative
TATA box sequence 29 bp upstream is boxed. The uppercase sequence represents the transcribed region. The translation start codon
ATG is in bold font. The intron and exons 1/1a are as indicated. The partial translated amino acid sequence is in uppercase and
underlined. Potential transcription factor binding sites are in uppercase and underlined with the name above. PAX-5, B-cell-specific
activating protein; HOX, PBX1 and MEIS1, family of homeodomain-containing transcription factors; PR, progesterone receptor binding
site. ‘x’ indicates the start site of 59-UTR and exon 1a. (B) Schematic diagram for transcription factor binding sites in the KLK5
promoter region.
59 KLK7 exons (exons 1a, 1b or 1c) are utilised in the
pancreas (exons 1a and 1b). As shown in Figure 3C, the
pancreatic KLK7 mRNA transcripts have the same cod-
ing region as skin and ovarian long transcripts, which
would be translated into full-length KLK7, but is different
from the ovarian short KLK7 transcript (AF414215) which
encodes an N-terminal truncated protein, because exon
1 is missing. On the other hand, the pancreatic tran-
scripts have different 59-UTR and 39-UTR from ovary and
skin, suggesting the usage of alternative promoters and
different transcriptional regulation in these organs.
Pancreas-specific transcription factor binding sites
in KLK5 and KLK7 promoters
We also examined the genomic nucleotide sequence of
the proximal promoter region of KLK5 (Figure 4) and
KLK7 (Figure 5) to identify consensus basal and tissue-
specific regulatory elements. A potential TATA box was
localised 29 bp upstream from the identified pancreatic
TIS for KLK5 (ttataa, Figure 4A) and KLK7 (atataa, Figure
5A) obtained from 59-RLM-RACE approaches. Using the
MatInspector program, which has been used for KLK6
promoter region analysis (Christophi et al., 2004), in silico
analysis of approximately 2 kb immediately 59 to the TIS
of KLK5 (GenBank: AF135028) and KLK7 (AF166330)
revealed a number of pancreatic-specific transcription
factor binding sites in this region. For instance, the
sequences of binding sites for the PBC family of homeo-
domain protein PBX1, three amino acid loop extension
(TALE) family member MEIS1, B-cell-specific activating
protein PAX-5 and HOX protein were found in the KLK5
promoter (Figure 4). In the KLK7 promoter region, tran-
scription factor binding sites were also found for PDX1,
PBX1, MEIS2, PAX-5 and HOX (Figure 5). In addition,
nuclear receptor regulatory binding sites for the proges-
terone receptor (PR) were found in the KLK5 promoter
region (Figure 4), while androgen receptor (AR) and glu-
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Figure 5 Sequence analysis of the human KLK7 promoter.
(A) Nucleotide sequence of the proximal promoter and 59-flanking region of KLK7. The TIS is indicated by the arrow and a putative
TATA box sequence 29 bp upstream is boxed. The uppercase sequence represents the transcribed region. The translation start codon
ATG is in bold font. The intron and exon 1/1a are as indicated. The partial translated amino acid sequence is in uppercase and
underlined. Potential transcription factor binding sites are in uppercases and underlined with the name above. PDX1, pancreatic LIM-
homeodomain transcription factor; PAX-5, B-cell-specific activating protein; HOX and MEIS1, family of homeodomain-containing
transcription factors homeobox protein; PR, progesterone receptor binding site; AR, androgen receptor binding site; GR, glucocor-
ticoid receptor. ‘x’ indicates start site of 59-UTR and exon 1a. (B) Schematic diagram for transcription factor binding sites in the
KLK7 promoter region.
cocorticoid receptor (GR) binding elements were identi-
fied in the KLK7 promoter region (Figure 5).
KLK5 and KLK7 are expressed in pancreatic tissues
by acinar cells
Because KLK5 can activate KLK7 in vitro (Brattsand et
al., 2005) and the co-localisation of these proteins in skin
and ovary has been reported (Dong et al., 2003),
immunohistochemical staining was performed to exam-
ine the cellular localisation of these proteins in pancreatic
tissues (Figure 6). Both KLK5 and KLK7 staining was
confined to acinar cells (open arrows in Figure 6A–C for
KLK5, open arrows in Figure 6D,E for KLK7), where KLK5
and KLK7 staining can be observed in the cytoplasm
only (Figure 6A–E). KLK5 staining was essentially homo-
genous throughout the cytoplasm of acinar cells (open
arrows, Figure 6A), whereas KLK7 displayed granular
staining of these cells (open arrows, Figure 6E). KLK7
also displayed clear staining in ducts (arrowhead in Fig-
ure 6D), indicating secretion from the pancreas, whereas
only faint ductal staining was observed for KLK5
(arrowheads, Figure 6B,C). Faint staining on the islet of
Langerhans (black arrows in Figure 6B for KLK5; Figure
6D for KLK7), but no stromal cell staining (open arrow-
heads in Figure 6B,C for KLK5; open arrowhead in Figure
6D for KLK7) was observed. No staining was observed
in the negative controls with primary antibody omitted
(Figure 6F).
Discussion
We have demonstrated by Northern blot analysis that
specific clusters of KLK genes (KLK5–13 and
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Figure 6 Localisation of KLK5 and KLK7 in human pancreas tissues by immunohistochemical staining.
KLK5 expression was detected with the anti-active-KLK5 antibody and KLK7 expression was detected with anti-recombinant KLK7
antibody as described in the materials and methods section. (A) Acinar cells with cytoplasmic KLK5 staining (open arrows).
(B) Cytoplasmic staining of KLK5 in acinar cells (open arrows), but faint staining of KLK5 in the islet of Langerhans (black arrows), a
small duct (arrow head) and stromal tissue (open arrowhead). (C) Another tissue section showing KLK5 expression in acinar cells
(open arrows), with faint staining of small ducts (arrowheads) and stromal tissue (open arrowhead). (D) Granular cytoplasmic KLK7
staining in acinar cells (open arrows) and the ductal epithelium (arrowhead), faint staining of islet of Langerhans (arrow), but no
staining on the surrounding stromal tissue (open arrowhead). (E) Another tissue section displaying secretory granular cytoplasmic
staining (open arrows). (F) Negative control (10% normal goat serum instead of primary antibody) showing no staining. Panels (A–D)
and (F) have the same magnification as indicated in panel (C).
KLK1:KLK15) display a common pancreatic expression.
Although the size of the pancreatic transcripts (1.0 kb)
was generally comparable for all these genes, several dif-
ferent transcript lengths were observed in other tissues.
KLK5 and KLK7 transcripts from the pancreas were also
compared with transcripts from keratinocyte and ovarian
cancer cell lines. Consistent with abundant expression
only in pancreas, a number of consensus pancreatic-
specific transcription factor binding sites were detected
in the KLK5 and KLK7 promoters. We have additionally
shown for the first time that the KLK5 and KLK7 proteins
are expressed in pancreatic tissues by acinar cells, sug-
gesting a specific role in these cells.
The expression patterns of the KLK gene family have
been extensively examined using the sensitive RT-PCR
and ELISA methods with varying degrees of expression
reported for all 15 family members in a wide range of
tissues and cell lines (Gan et al., 2000; Harvey et al.,
2000; Borgono et al., 2004; Clements et al., 2004; Shaw
and Diamandis, 2007). However, it has also been report-
ed that Northern blot and mRNA dot blot analyses indi-
cated that abundant expression levels for the KLKs is
restricted to a limited number of tissues (Harvey et al.,
2000; Clements et al., 2004). Our present Northern blot
analysis data show a similar restricted expression profile
for several KLKs (KLK5–KLK13, KLK15) and in particular
in the pancreas. The prostate is also a major site of
expression for KLK4, KLK6, KLK8, KLK10, KLK11,
KLK14 and KLK15. High expression for KLK5, KLK10
and KLK11 was also observed in testis, for KLK10 in
ovary, KLK6 in heart and KLK10 in thymus. The expres-
sion of these and other KLKs in various human tissues
and associations with human diseases, including cancer
have been well reviewed (Borgono et al., 2004; Clements
et al., 2004). These results suggest two major clusters of
KLK abundant expression in the pancreas and prostate,
implying the function of KLK enzymes in these normal
glands, as well as potentially tissue associated patholog-
ical conditions, such as diabetes and cancer. Further-
more, high expression of KLK5/KLK5 and KLK7/KLK7
has also been found in ovarian cancer (Tanimoto et al.,
1999; Yousef et al., 2002; Dong et al., 2003), suggesting
that these two enzymes may play roles in cancer pro-
gression, perhaps by enabling shedding of cancer cells
into the peritoneum and facilitating local invasion.
Our data also add weight to the proposition that the
KLK locus has arisen as a result of gene duplication.
Indeed, intriguingly, a recent phylogenetic study of the
KLK family suggested that gene duplication occurred
more randomly than previously proposed and links KLK8
most closely with KLK1 (Elliott et al., 2006). KLK9, KLK11
and KLK15 are linked in one tree, KLK10 and KLK12 are
suggested as duplicates of KLK9 and KLK11, and KLK7
and KLK13 as sister taxa (Elliott et al., 2006). KLK4, KLK5
and KLK14 are aligned on one tree, with KLK4 and KLK5
suggested as direct duplicates, while KLK6 is thought
to be the gene which diverged first. The expression pro-
files of these genes may also be useful indicators of sis-
ter taxa relationships, depending on the extent to which
gene flanking sequences that harbour expression regu-
latory elements have also been duplicated. In this case,
our observation of high expression of KLK8 in pancreas,
and to a lesser extent in prostate, would support linkage
to the classical pancreatic KLK1 gene and the prostate-
restricted KLK2 and KLK3 genes. Similarly, KLK15 and
KLK11 have identical expression profiles (pancreas,
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prostate and testis) as do KLK7 and KLK13 (pancreatic-
restricted). Less clear is the suggested duplication of
KLK4 and KLK5, given the prostate restricted expression
of KLK4, yet strong pancreatic and testicular expression
of KLK5, but no prostatic expression. Nonetheless, the
inclusion of expression profiles when attempting to
determine which genes are sister taxa and the result of
gene duplication may help unravel the precise evolution-
ary events that occurred.
The KLK family of 15 genes is a multi-transcript rich
family. Multiple transcripts arising from alternate splicing
retained intronic segments, exon deletion or utilisation of
alternate TISs have all been described (Kurlender et al.,
2005; Tan et al., 2006). To date, more than 80 transcripts
have been described (Kurlender et al., 2005; Tan et al.,
2006), with at least two transcripts (KLK10 and KLK14)
(Hooper et al., 2001; Kurlender et al., 2005; Tan et al.,
2006) for each gene and up to 11 variants for the
PSA/KLK3 gene (as reviewed by Kurlender et al., 2005;
Tan et al., 2006). Indeed, the multiple bands of different
sizes observed from our present Northern blot data (Fig-
ure 1) clearly reflect these findings. For instance, there
are at least four KLK6 transcripts expressed in prostate
and three KLK9 transcripts in pancreas. Of interest, the
size of the pancreatic transcripts for all KLK genes
expressed in this tissue (KLK5, KLK6, KLK8, KLK10 and
KLK11) is smaller than that observed in other tissues, but
comparable to that reported for KLK1, suggesting that
there is specific transcriptional machinery utilised for all
these genes when expressed in the pancreas.
The KLK7 transcript identified by RLM-RACE from
pancreas here further confirmed expression of this gene
in the pancreas and tissue-specific differences from that
expressed in skin or ovary. However, as the only differ-
ence is in the 59-UTR with no alteration in coding region,
these KLK7 transcripts would encode the same full-
length KLK7 enzyme, suggesting its potential serine pro-
tease function in pancreas as well as skin and ovary.
Similar tissue specific transcripts with varying 59-UTRs
have been previously reported for KLK11 between pros-
tate and brain tissues (Mitsui et al., 2000). We and others
have previously reported that distinct forms of KLK3,
KLK4, KLK5, KLK7, and KLK11, each the result of alter-
nate mRNA splicing, are expressed in malignant tumour
cells (reviewed in Tan et al., 2006). In the case of KLK5,
the presence of different 59-UTRs in ovarian cancer cells
indicates selective use of different promoters in a tumour-
specific fashion (Dong et al., 2003). Another unique 59-
UTR in a KLK6 transcript was recently found to be
expressed in demyelination and inflammatory diseases of
the central nervous system (Christophi et al., 2004). Tak-
en together, these findings suggest that tissue- or dis-
ease-specific transcripts use alternate promoters and
that these regions likely harbour tissue-specific elements
directing their expression.
Indeed, our in silico analyses revealed that consensus
transcription factor binding sites involved in the regul-
ation of the endocrine and exocrine pancreas, such as
PBX and MEIS (Swift et al., 1998), are localised in the
59-flanking region of both KLK5 and KLK7. Interestingly,
in the KLK7 promoter, we found a putative binding site
for the crucial developmental regulator PDX1 (Hale et al.,
2005), which in other genes functions by binding the co-
regulators PBX and MEIS. An example is the elastase 1
gene (ELA1), where the PDX1/PBX1/MEIS2 complex
binds to enhancer components of the gene to direct its
acinar-specific expression (Swift et al., 1998). Further-
more, PBX1 and PDX1 are required not only for early
pancreatic development but also for the genesis of acinar
tissue, the compartment of the pancreas that produces
digestive enzymes (Kim and MacDonald, 2002; Muhar-
ram et al., 2005). Of note, MEIS1, not MEIS2 consensus
elements were found in both KLK5 and KLK7 promoter
regions, and therefore this homologue may play a similar
role (Geerts et al., 2005), although its function and that
of these other pancreatic transcription factors in KLK
gene regulation needs to be experimentally confirmed.
Consistent with these findings, our immunohistochem-
istry (IHC) staining showed that the expression of KLK5
and KLK7 was predominantly localised in the acini of the
exocrine pancreas, with less in islets of Langerhans.
These data suggest the involvement of KLK5 and KLK7
in the digestive function of the pancreas, perhaps in the
activation of other secreted enzymes in the digestive
pathway (Borgono and Diamandis, 2004; Clements et al.,
2004). Indeed, the KLK7 staining pattern was indicative
of secretory granules in the acini, which function to
secrete the digestive enzymes (Wasle and Edwardson,
2002). In contrast, KLK5 showed predominant uniform
staining on acinar cells with faint staining throughout the
rest of the cells, suggesting a different cellular function.
Furthermore, a protective role in the pancreas is possible
for KLK5, as this enzyme is a potential activator for
protease activated receptors 1 and 2 (Oikonomopoulou
et al., 2006), which play important roles in protection
against pancreatitis by stimulating exocrine secretion
(Singh et al., 2007). However, direct or indirect roles of
KLKs in exocrine or endocrine pancreas function remain
to be investigated. Of note, KLK5 can activate KLK7 in
skin and both are involved in the degradation of extra
cellular matrix and play important roles in the desqua-
mation of skin (Brattsand et al., 2005). Whether these
proteases will have similar roles in pancreatic matrix
remodelling or simply act as activators of other pancre-
atic proteins is yet to be established.
KLK1, also the first-named pancreatic kallikrein, has
been described in the b-cells of the pancreas (ole-MoiYoi
et al., 1979), but also has a strong exocrine cell local-
isation (Chao et al., 1980). Interestingly, KLK6, KLK10
and KLK13 were reported to be localised to the islets of
Langerhans (Petraki et al., 2002, 2003), suggesting dif-
ferent roles from KLK5 or KLK7 and providing further evi-
dence of the diverse functions of these proteases. KLK6
and KLK10 were also detected in endocrine-related neo-
plasms, including tumours producing glucagon or soma-
tostatin, and foci of endocrine dysplasia (Petraki et al.,
2002). It would also be interesting to examine the expres-
sion of KLK5 and KLK7 in exocrine- or endocrine-derived
pancreatic tumours. The different localisation observed
between the above kallikrein-related peptidases may
result from the regulation of exocrine and endocrine
expression by similar promoter specific elements. Thus,
the potential transcription factor binding sites that we
identified in the KLK5 and KLK7 promoters may effect
acinar cell expression in the pancreas. Furthermore, pro-
moter regions of other KLK genes remain to be invest-
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igated for the presence of motifs directing endocrine and
exocrine expression in the pancreas.
We have demonstrated strong expression of KLK5 and
KLK7 mRNA and protein in normal pancreas. In contrast,
a recent report did not detect KLK5 or KLK7 mRNA or
protein in this tissue (Shaw and Diamandis, 2007), while
another report detected only low levels of KLK7 mRNA
and protein in normal pancreas (Johnson et al., 2007).
These differences are likely due to variations in the
employed approaches. Of particular relevance, in con-
trast to our TIS identification, 39-RACE and Northern blot
analyses, which employed pancreatic poly(A)q RNA,
Shaw and Diamandis (2007) and Johnson et al. (2007)
used total RNA in their respective semi-quantitative RT-
PCR protocols. Furthermore, although different primer
sets were used by each research group, this is unlikely
to explain the differences in observed expression levels,
as overlapping sequences were amplified by all three
groups. In addition, the protocol employed by us to ana-
lyse KLK5 and KLK7 protein levels in pancreas differed
from those employed by Johnson et al. (2007) and Shaw
and Diamandis (2007). Although the former group also
used IHC to detect KLK7 in pancreas, these authors
employed citric acid antigen retrieval, whereas we used
urea in this step of the protocol. In contrast, Shaw and
Diamandis (2007) used capture ELISA protocols to ana-
lyse the levels of kallikreins in embryonic and adult tissue
extracts. It is not clear why this group failed to detect
KLK5 and KLK7 in pancreas extracts. However, it is inter-
esting to note that the goat anti-KLK7 antibody used by
Johnson et al. (2007) was generated against the same
antigen (recombinant KLK7 residues 23–252) as the
monoclonal antibody used by Shaw and Diamandis
(2007); although, the goat antibody detected KLK7 in
pancreas using IHC, the monoclonal antibody failed to
detect KLK7 in pancreas tissue.
In summary, using Northern blot analysis, we have
demonstrated a common and high expression of
KLK5–13 and KLK15 (which is contiguous to the first
described pancreatic KLK1 gene) in the pancreas. These
data provide further evidence supporting the gene dupli-
cation evolution of this family and suggest common reg-
ulatory elements or locus control regions that confer
tissue-specific expression. We have also identified
specific pancreatic KLK5 and KLK7 transcripts which, in
comparison with those in skin (HaCat) and ovarian
(OVCAR-3) cell lines show the presence of tissue-specific
TIS and 59-UTR sequences. We have shown the locali-
sation of KLK5 and KLK7 in the acinar cells of pancreatic
tissues consistent with our in silico analysis, which locat-
ed several potential pancreatic exocrine regulatory ele-
ments in the promoter regions of these genes. This study
has provided the basis for further investigation into the
molecular mechanisms underlying KLK5 and KLK7 reg-
ulation in different tissues and especially in the pancreas.
Materials and methods
Cell lines, RNA and tissue samples
Both the keratinocyte cell line HaCat and ovarian cancer cell line
OVCAR-3 were from the American Tissue Culture Collection
(ATCC, Manassas, VA, USA). All cell lines were cultured in RPMI-
1640 medium (Invitrogen, Mount Waverley, Australia) with 10%
foetal calf serum supplemented with 1% penicillin and strepto-
mycin (CSL Biosciences, Parkville, Australia) and incubated at
378C with 5% CO2. Poly(A)q RNA was purchased as a pooled
sampled from pancreatic tissues of 15 males and females who
died suddenly (Clontech, Mountain View, CA, USA). Mycoplas-
ma testing for cultured cells was performed every 4–6 weeks
using a Mycoplasma Detection kit (Roche, Brisbane, Australia).
Northern blot analysis
Human multiple tissue Northern blots containing poly(A)q RNA
were purchased (Clontech) and hybridised as described prev-
iously (Harvey et al., 2000).
Transcription initiation site and cDNA 39-end
identification
Transcription initiation site identification was performed by
59-RNA ligase mediated rapid amplification of cDNA ends (RLM-
RACE) using a FirstChoice RLM-RACE kit (Ambion, Austin, TX,
USA), according to the manufacturer’s instructions. Briefly, after
treatment of calf intestinal phosphatase and tobacco acid pyro-
phosphatase (TAP), an RNA oligonucleotide was ligated to full-
length, decapped mRNAs, and then reverse transcription was
performed using random primers supplied from the kit. Using
this approach, incomplete mRNAs are eliminated using alkaline
phosphatase and the mRNA cap structure is removed using TAP
to ensure only full-length transcripts are amplified (Maruyama
and Sugano, 1994). PCR was performed using the 59-outer pri-
mer from the RLM-RACE kit and a KLK5 (pancreas, 59-GAG AAC
ATG CTC TGT GAC CCC C-39; HaCat and OVCAR-3, 59-AGA
CGG ACT CTG AAA ACT TTC TT-39) or KLK7 specific primer
(pancreas, 59-ATG AGG TCA TTA ACA TGG GTC T-39; HaCat and
OVCAR-3, 59-CAA AGG CTA AGG ATA GCA GTA AGA TCT-39).
A second round of PCR was then performed using the 59-inner
primer from the kit and a nested KLK5 (pancreas, 59-TCT GAT
CAC AGC CTT GCT TCT GGG GGT CA-39; HaCat and
OVCAR-3, 59-GAG CTG GGG CCG GGG AAG AC-39) or KLK7
specific primer (pancreas, 59-AGA TCT TAC TGC TAT CCT TAG
CCT TG-39; HaCat, 59-CAT TAA CAT GGG TCT GTG TGG AGT
AGC C-39; OVCAR-3, 59-CAG TGG AGC TGA TTG CCA CTG
A-39). Amplification conditions were 35 or 45 cycles for 1 min
with annealing temperatures of 558C for the first round and 628C
for the second round PCR. For cDNA 39-end identification, 39-
RACE was employed using the universal 39-UTR primer (Pro-
mega, Madison, WI, USA) followed by PCR using 1 ml of the
cDNA reaction and KLK5- or KLK7-specific primers as
described previously (Dong et al., 2003).
In silico analysis of KLK genes using serial analysis
gene expression (SAGE; SAGEmap) and expression
sequence tag (EST) databases
The 15 human KLK mRNA sequences were used to identify
unique sequence tags of UniGene clusters for each KLK. The
respective GenBank entries for KLK1–15 were M33105,
M18157, M27274, AF148532, NM_012427, AF013988, L33404,
AB009849, AF135026, BC002710/NM_002776, AB012917,
NM_145894, BC069334, AF283669 and NM_023006. The
sequence tags anchored by restriction digestion enzymes NIaIII
and Sau3A were used to determine the expression of different
KLKs in pancreatic libraries (3 from normal and 6 from cancer)
and a list of all libraries were found at http://www.ncbi.nlm.
nlh.gov/geo/gds/.
The full-length mRNA sequence of each KLK was also com-
pared against the human EST databases of the National Centre
for Biotechnology Information (NCBI). At the time of the study,
these databases contained 8 normal and 10 carcinoma pancre-
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atic libraries. Expression was determined by identification of
positive clones with more than 95% homology to each KLK in
these libraries.
DNA sequence analysis of EST clones and PCR
products
DNA of two KLK pancreatic EST clones (GenBank AA101043
and AA101044; Invitrogen) with )95% homology to KLK7
(GenBank: NM_005046) was sequenced at the Australian
Genome Research Facility (Brisbane, Australia) and analysed
using tBLASTN (www.ncbi.nlm.nih.gov/blast).
Identification of consensus transcription factor
binding sites
The sequence upstream of the TIS for both KLK5 (GenBank:
AF135028) and KLK7 (GenBank: AF166330) was analysed for
transcription factor binding sites using the MatInspector pro-
gram (www.gene-regulation.com/cgi-bin/pub/programs/tfblast/
tfblast.cgi), and confirmed using the rVista2.0 algorithm
(www.dcode.org).
Immunohistochemistry (IHC)
Institutional ethics committee approval was obtained for the use
of normal pancreatic tissues collected at autopsy. Six paraffin-
embedded pancreatic tissue blocks were sectioned (4 mm),
deparaffinised and rehydrated. IHC was performed as described
previously (Dong et al., 2003), using an affinity purified anti-KLK5
peptide antibody (3 mg/ml) (Dong et al., 2003) or an affinity puri-
fied anti-recombinant KLK7 antibody (3 mg/ml) (Ekholm and
Egelrud, 1998; Ekholm et al., 2000; Dong et al., 2003). Antigen
retrieval was performed by microwave heat treatment in 5% urea
in 0.1 M Tris buffer (pH 9.5). Normal goat serum (10%) instead
of primary antibody was used for negative controls.
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